0001520138-24-000079.txt : 20240301 0001520138-24-000079.hdr.sgml : 20240301 20240301094039 ACCESSION NUMBER: 0001520138-24-000079 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240301 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240301 DATE AS OF CHANGE: 20240301 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOVIE INC. CENTRAL INDEX KEY: 0001580149 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 462510769 STATE OF INCORPORATION: NV FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39015 FILM NUMBER: 24707481 BUSINESS ADDRESS: STREET 1: 680 W NYE LANE STREET 2: SUITE 201 CITY: CARSON CITY STATE: NV ZIP: 89703 BUSINESS PHONE: 775-888-3162 MAIL ADDRESS: STREET 1: 680 W NYE LANE STREET 2: SUITE 201 CITY: CARSON CITY STATE: NV ZIP: 89703 FORMER COMPANY: FORMER CONFORMED NAME: NANOANTIBIOTICS, INC. DATE OF NAME CHANGE: 20130625 8-K 1 bivi-20240301_8k.htm CURRENT REPORT
false 0001580149 0001580149 2024-03-01 2024-03-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported) March 1, 2024

 

BioVie Inc.
(Exact Name of Registrant as Specified in Its Charter)

 

Nevada   001-39015   46-2510769
(State or Other Jurisdiction of Incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)

 

680 W Nye Lane Suite 201

Carson City, NV

   89703
(Address of Principal Executive Offices)   (Zip Code)

 

(775) 888-3162
(Registrant’s Telephone Number, Including Area Code)

 

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Class A Common Stock, par value $0.0001 per share BIVI The Nasdaq Stock Market, LLC

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

Item 8.01 Other Events.

 

On March 1, 2024, BioVie Inc. (the “Company”) issued a press release announcing the presentation of “Improvement of Non-Motor Symptoms with NE3107 Adjunctive to Carbidopa/Levodopa in Patients with Parkinson’s Disease: A Phase 2A, Placebo-Controlled Study” and “Clinical Outcomes from a Phase 3, Randomized, Placebo-Controlled Trial of NE3107 in Subjects with Mild to Moderate Probable Alzheimer’s Disease” at the International Conference on Alzheimer’s and Parkinson’s Diseases 2024 in Lisbon, Portugal.

 

The Company is filing a copy of the press release, which is attached hereto as Exhibit 99.1 and incorporated herein by reference.

 

Forward-Looking Statements

 

This Current Report on Form 8-K contains forward-looking statements, which may be identified by words such as “expect,” “look forward to,” “anticipate” “intend,” “plan,” “believe,” “seek,” “estimate,” “will,” “project” or words of similar meaning. In this report, forward-looking statements include, but are not limited to, the potential impact of NE3107 on cognition and function among study participants and topline data from the NE3107 trial. Although the Company believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Actual results may vary materially from those expressed or implied by the statements herein due to certain risks, including but are not limited to, the Company’s ability to successfully raise sufficient capital on reasonable terms or at all, available cash on hand and contractual and statutory limitations that could impair the Company’s ability to pay future dividends, the Company’s ability to complete the Company’s pre-clinical or clinical studies and to obtain approval for the Company’s product candidates, the Company’s ability to successfully defend potential future litigation, changes in local or national economic conditions as well as various additional risks, many of which are now unknown and generally out of the Company’s control, and which are detailed from time to time in reports filed by the Company with the Securities and Exchange Commission, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. The Company does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law.

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits.

 

Exhibit No.   Description
99.1   Press Release dated March 1, 2024.
104   Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101)

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: March 1, 2024

 

  BIOVIE INC.
     
  By: /s/ Joanne Wendy Kim
  Name:   Joanne Wendy Kim
  Title: Chief Financial Officer

 

 

 

 EX-99.1 2 bivi-20240301_8kex99z1.htm EXHIBIT 99.1

BioVie’s NE3107 Demonstrates Potential Improvements in Motor and Non-motor Symptoms for Parkinson’s Disease Patients and May Be Realigning Physiological Processes for Alzheimer’s Patients in Data to be Presented at the International Conference on Alzheimer’s and Parkinson’s Diseases 2024

 

Data from Phase 2a trial in Parkinson’s Disease suggest patients treated with NE3107 experienced significant improvements in non-motor symptoms and motor control while placebo-treated patients worsened

 

Data from Phase 3 trial in mild to moderate Alzheimer’s Disease suggest NE3107 may have the potential to realign physiological processes in patients consistent with decreased neurocognitive decline and diseases of aging

 

Carson City NV, March 1, 2024 – BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced two upcoming presentations at the International Conference on Alzheimer’s and Parkinson’s Diseases 2024 (AD/PD™ 2024) to be held March 5-9, 2024 in Lisbon, Portugal.

 

Improvements in non-motor symptoms correlated with improvements in motor symptoms for Parkinson’s Disease patients

 

The presentation Improvement of Non-Motor Symptoms with NE3107 Adjunctive to Carbidopa/Levodopa in Patients with Parkinson’s Disease: A Phase 2A, Placebo-Controlled Study will be presented at 15:10 GMT on March 9, 2024 and suggest improvements of NE3107-treated patients with non-motor symptoms. These findings complement previously reported improvement in motor symptoms in patients treated with NE3107 and demonstrate potential intrinsic, levodopa-enhancing activity of NE3107 that is consistent with data from animal models.

 

NE3107-treated patients experienced a significant improvement of -2.4 points for the sleep/fatigue domain of the Non-Motor Symptom Scale (NMSS) in Parkinson’s Disease, whereas placebo patients experienced a worsening of +1.0 points (p=0.0159). Sleep/fatigue domain improvements correlated with motor score improvements (r=0.51; p=0.0259). More patients on NE3107 had improvements in the NMSS sleep/fatigue domain, while more patients on placebo worsened.

 

NMSS changes for NE3107-treated patients were driven by improvements of -0.87 in fatigue/lack of energy (p= 0.0005) and improvement of -2.91 on the urge to move legs/restlessness in legs (p=0.0036). Placebo patients saw no significant change of -0.39 on fatigue (p=0.1242) and -0.71 on leg restlessness (p=0.5141).

 



 

 

 

The new data on non-motor improvements complements previously presented data1 showing NE3107-treated patients saw a 3+ points advantage compared to placebo on the Part 3 (motor) score of the Motor Disease Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS). In patients younger than 70 years old, the advantage was over 6 points. Furthermore, 26% of NE3107-treated patients experienced improvement in their ability to move, having Part 3 scores prior to their first morning dose of carbidopa/levodopa that were equal to or better than Part 3 scores associated with their being in the “on” state after carbidopa/levodopa treatment at the start of the study, whereas none of the placebo patients had the similarly improved morning Part 3 scores. The difference was statistically significant (p=0.046).

 

“These data suggest that NE3107 as adjunct therapy to levodopa may hold promise in ameliorating specific non-motor symptoms of Parkinson’s Disease, particularly in sleep/fatigue and restlessness of the legs,” stated Joseph Palumbo, BioVie’s Chief Medical Officer. “These findings extend previously reported improvement in motor symptoms with NE3107 and demonstrate potential intrinsic and levodopa-enhancing activity of NE3107 that is consistent with data from animal models and support further clinical investigation of NE3107 in late-phase trials.”

 

Possible physiological realignment in Alzheimer’s Disease

 

The presentation Clinical Outcomes from a Phase 3, Randomized, Placebo-Controlled Trial of NE3107 in Subjects with Mild to Moderate Probable Alzheimer’s Disease will be presented at 14:50 GMT on March 8, 2024 reconfirms topline cognitive and functional data previously presented and will provide additional biomarker data and analyses.

 

The NM101 Trial enrolled 439 patients through 39 sites. The Company previously reported that upon trial completion, significant deviation from protocol and Good Clinical Practice violations were found at 15 sites, causing the Company to exclude all patients from these sites. After these exclusions and other exclusions per the statistical analysis plan, 57 patients in the Per-Protocol population were verified to have taken study drug from pharmacokinetics data and completed the full duration of the trial. Baseline and completion data were available for 50 subjects (NE3107, n=24 and placebo, n=26; 7 subjects randomized to placebo discontinued before day 150), and DNA methylation data were available for 33 subjects in this cohort.

 

Due to the exclusion of data from so many sites the trial missed statistical significance but showed promising directional data on cognitive and functional measures. NE3107-treated patients saw an advantage compared to placebo of -0.95 (68% slowing of decline) on CDR-SB, -0.94 (26%) on ADAS-COG-12, -0.43 (139%) on ADAS-CGIC, -0.03 (27%) on ADCOMS, +1.02 (40%) on MMSE, and +3.08 (47%) on ADCS-ADL.2

 

 

1A Randomized, Phase 2a, Double-Blind, Placebo-Controlled Clinical Trial With NE3107 Adjunctive to Carbidopa/Levodopa in Patients With Parkinson’s Disease. Presented at the 2023 International Congress of Parkinson’s Disease and Movement Disorders, August 27-31, 2023 in Copenhagen, Denmark
2ADAS-Cog12 = 12-item cognitive subscale of the Alzheimer’s Disease Assessment Scale (lower is improvement); ADCOMS = Alzheimer’s Disease Composite Score (lower is improvement); ADCS-ADL = Alzheimer’s Disease Cooperative Study-Activities of Daily Living (higher is improvement); ADCS-CGIC = Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change (lower is improvement); CDR-SB = Clinical Dementia Rating, Sum of Boxes (lower is improvement), MMSE = Mini Mental State Examination (higher is improvement).

 

- 2 -

 

 

Significant improvements for NE3107-treated patients vs. placebo were observed for biological age deceleration (-3.87 years, p=0.012), fasting glucose levels (-8.5 mg/dL, p=0.036), cholesterol (-15 mg/dL, p=0.049), HOMA2 beta cell function (+12.4%, p=0.040), HOMA2 Insulin Sensitivity (+1.95%, p=0.018), and MCP1 (-90.5 pg/mL, p=0.007). Trending improvements in HOMA2 Insulin Resistance of -0.020 (p=0.0.063) were also observed.

 

A statistical technique called Principal Component Analysis3 identified neurological assessments and biological age deceleration as the two “principal components” that maximally explained the data across the large set of variables collected. Among NE3107-treated patients, correlations of neurological assessments and biological age deceleration with improved metabolic and glycemic control, improved neuropsychiatric indices, and levels of chemokines associated with microglial attraction to and digestion of Aβ plaques. Among placebo patients, neurological assessments and biological age deceleration were correlated with increased metabolic inflammatory measures, M1 to M2 transition, and plaque phagocytosis.

 

“We previously reported that NE3107 appeared to decrease metabolic inflammation-driven systems dysregulation,” stated Chris Reading, BioVie’s Senior Vice President of Alzheimer’s Disease Programs. “Principal component analyses, divergent correlations, and epigenetic analysis suggest that metabolic inflammation may be a driver of biological aging and AD, and that NE3107 might have the potential to realign physiological processes consistent with decreased neurocognitive decline and diseases of aging.”

 

“The data being presented reinforce our confidence in the potential of NE3107 to have a meaningful impact on core symptoms of both Alzheimer’s disease and Parkinson’s disease,” stated Cuong Do, BioVie’s President and CEO. “These findings add to the growing body of evidence supporting our hypothesis that by selectively modulating inflammation and enhancing insulin sensitivity in the brain, NE3107 could offer benefits in slowing disease progression and improving the lives of patients living with these devastating conditions.”

 

About BioVie  

 

BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company’s drug candidate NE3107 inhibits inflammatory activation of ERK and NFkB (e.g., TNF signaling) that leads to neuroinflammation and insulin resistance, but not their homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both are drivers of Alzheimer’s and Parkinson’s diseases. The Company conducted and reported efficacy data from its randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer’s disease (NCT04669028). Results of a Phase 2 investigator-initiated trial (NCT05227820) showing NE3107-treated patients experienced improved cognition and biomarker levels were presented at the Clinical Trial in Alzheimer’s Disease (CTAD) annual conference in December 2022. An estimated six million Americans suffer from Alzheimer’s. A Phase 2 study of NE3107 in Parkinson’s disease (NCT05083260) has completed, and data presented at the International Conference on Alzheimer’s and Parkinson’s Disease and Related Neurological Disorders conference in Gothenburg, Sweden in March 2023 showed significant improvements in “morning on” symptoms and clinically meaningful improvement in motor control in patients treated with a combination of NE3107 and levodopa vs. patients treated with levodopa alone, and no drug-related adverse events. In liver disease, the Company’s Orphan drug candidate BIV201 (continuous infusion terlipressin), with U.S. Food and Drug Administration (FDA) Fast Track status, is being evaluated and discussed with guidance received from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the treatment of ascites due to chronic liver cirrhosis. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis. For more information, visit http://www.bioviepharma.com/. 

 

 

3Principal component analysis is a statistical method for identifying/combining separate variables to a few “principal components” that maximally explain the variance of all the underlying variables. In the process, the method provides an approximation of the original data represented by the many individual variables using only a few major components.

 

- 3 -

 

 

Forward-Looking Statements 

This press release contains forward-looking statements, which may be identified by words such as “expect,” “look forward to,” “anticipate” “intend,” “plan,” “believe,” “seek,” “estimate,” “will,” “project” or words of similar meaning. In this press release, forward-looking statements include, but are not limited to, the potential impact of NE3107 on cognition and function among study participants and topline data from the NE3107 trial. Although BioVie Inc. believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Actual results may vary materially from those expressed or implied by the statements herein due to the Company’s ability to successfully raise sufficient capital on reasonable terms or at all, available cash on hand and contractual and statutory limitations that could impair our ability to pay future dividends, our ability to complete our pre-clinical or clinical studies and to obtain approval for our product candidates, our ability to successfully defend potential future litigation, changes in local or national economic conditions as well as various additional risks, many of which are now unknown and generally out of the Company’s control, and which are detailed from time to time in reports filed by the Company with the SEC, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. BioVie Inc. does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law.

 

For Investor Relations Inquiries: 

 

Contact: 
Bruce Mackle 
Managing Director 
LifeSci Advisors, LLC 
bmackle@lifesciadvisors.com 

   

For Media Inquires

Melyssa Weible

Managing Partner, Elixir Health Public Relations 

Ph: +1 201-723-5705

mweible@elixirhealthpr.com

 

- 4 -

 

 EX-101.SCH 3 bivi-20240301.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 bivi-20240301_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 bivi-20240301_pre.xml XBRL PRESENTATION FILE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover
Mar. 01, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 01, 2024
Entity File Number 001-39015
Entity Registrant Name BioVie Inc.
Entity Central Index Key 0001580149
Entity Tax Identification Number 46-2510769
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 680 W Nye Lane
Entity Address, Address Line Two Suite 201
Entity Address, City or Town Carson City
Entity Address, State or Province NV
Entity Address, Postal Zip Code 89703
City Area Code (775)
Local Phone Number 888-3162
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Class A Common Stock, par value $0.0001 per share
Trading Symbol BIVI
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://bioviepharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports bivi-20240301.xsd bivi-20240301_8k.htm bivi-20240301_lab.xml bivi-20240301_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "bivi-20240301_8k.htm": { "nsprefix": "bivi", "nsuri": "http://bioviepharma.com/20240301", "dts": { "schema": { "local": [ "bivi-20240301.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "inline": { "local": [ "bivi-20240301_8k.htm" ] }, "labelLink": { "local": [ "bivi-20240301_lab.xml" ] }, "presentationLink": { "local": [ "bivi-20240301_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://bioviepharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-03-01", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20240301_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-01", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20240301_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001520138-24-000079-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001520138-24-000079-xbrl.zip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�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end XML 16 bivi-20240301_8k_htm.xml IDEA: XBRL DOCUMENT 0001580149 2024-03-01 2024-03-01 iso4217:USD shares iso4217:USD shares false 0001580149 8-K 2024-03-01 BioVie Inc. NV 001-39015 46-2510769 680 W Nye Lane Suite 201 Carson City NV 89703 (775) 888-3162 Class A Common Stock, par value $0.0001 per share BIVI NASDAQ false false false false false